Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer.
Di Palma
S
S
Histopathology, Royal Surrey County Hospital, Egerton Road, Guildford, Surrey GU2 7XX, UK. silvana.dipalma@royalssurrey.nhs.uk
Collins
N
N
Faulkes
C
C
Ping
B
B
Ferns
G
G
Haagsma
B
B
Layer
G
G
Kissin
M W
MW
Cook
M G
MG
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D018270:Carcinoma, Ductal, Breast / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D002863:Chromogenic Compounds; D005260:Female; D018734:Genes, erbB-2; D006801:Humans; D017403:In Situ Hybridization / Q000379:methods; D018579:Patient Selection; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D002863:Chromogenic Compounds; D000068878:Trastuzumab